145783-13-7

Basic information

• Product Name: 5-nitro-2-(propylthio)pyriMdine-4,6-diol
• Synonyms: 5-nitro-2-(propylthio)pyriMdine-4,6-diol;5-Nitro-2-(propylthio)pyriMidine-4,6-diol;4(3H)-PyriMidinone, 6-hydroxy-5-nitro-2-(propylthio)-;S-Propyl-5-nitro-2-thiobarbituric Acid;4-hydroxy-5-nitro-2-propylsulfanyl-1H-pyrimidin-6-one
• CAS NO: 145783-13-7
• Molecular Formula: C₇H₉N₃O₄S
• Molecular Weight: 231.22906
• EINECS: -0
• Mol File: 145783-13-7.mol

Chemical Properties

• Appearance: /
• Density: 1.65±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.21±0.10(Predicted)
• CAS DataBase Reference: 5-nitro-2-(propylthio)pyriMdine-4,6-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-nitro-2-(propylthio)pyriMdine-4,6-diol(145783-13-7)
• EPA Substance Registry System: 5-nitro-2-(propylthio)pyriMdine-4,6-diol(145783-13-7)

Safety Data

• Hazardous Substances Data: 145783-13-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-nitro-2-(propylthio)pyrimidine-4,6-diol is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and functional groups allow for the creation of new drug molecules with potential therapeutic applications.
Used in Materials Science:
5-nitro-2-(propylthio)pyrimidine-4,6-diol is used as a precursor in the development of novel materials with specific properties. Its chemical versatility can contribute to the design of advanced materials for various applications, such as in electronics, coatings, or other industrial products.
Used in Chemical Research:
5-nitro-2-(propylthio)pyrimidine-4,6-diol is used as a subject of study in chemical research to understand its reactivity, stability, and potential interactions with other compounds. This knowledge can lead to the discovery of new chemical reactions or the development of innovative applications in various fields.

Upstream product

• 145783-12-6 4,6-dihydroxy-2-(propylsulfanyl)pyrimidine 
• 106-94-5 propyl bromide 
• 107-08-4 1-iodo-propane 
• 187666-88-2 2-(Propylthio)-4,6(1H,5H)-pyrimidinedione 

Downstream Products

• 274693-26-4 [3aR-[3aα,4α,6α,(1R,2S),6aα]]-2-[6-[[[7-(2-(3,4-difluorophenyl)cyclopropyl)]amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-4H-cyclopenteno-1,3-dioxolan-4-yl]oxy]ethanol 
• 376608-74-1 2-[((3aR,4S,6R,6aS)-6-[[5-amino-6-chloro-2-(propylsulfanyl)-4-pyrimidinyl]amino]-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy]-1-ethanol 
• 376608-75-2 2-({(3aR,4S,6R,6aS)-6-[7-chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-yl]-2,2-dimethyltetrahydro-3aH-cyclopentadiene[d][1,3]dioxolene-4-yl}oxy)ethanol 
• 274693-27-5 ticagrelor 
• 145783-14-8 4,6-dichloro-5-nitro-2-(propylsulfanyl)pyrimidine 
• 1383715-58-9 tert-butyl (6-chloro-5-nitro-2-(propylthio)pyrimidin-4-yl)((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)carbamate 
• 1383715-59-0 2-[[(3aR,4S,6R,6aS)-6-[[4-[N-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-yl]-N-tert-butoxycarbonyl]amino]-2-(propylthio)-5-nitropyrimidin-6-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy] ethanol 
• 1383715-60-3 2-[[(3aR,4S,6R,6aS)-6-[[4-[N-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-yl]-N-tert-butoxycarbonyl]amino]-2-(propylthio)-5-aminopyrimidin-6-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol 
• 1383715-61-4 tert-butyl N-[3-[(3aS,4R,6S,6aR)-6-(2-hydroxyethoxy)-2,2-dimethyl-hexahydrocyclopenta[d][1,3]dioxol-4-yl]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl]-N-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]carbamate 
• 1383715-62-5 2-({(3aR,4S,6R,6aS)-6-[7-{[[N-(IR,2S)-2-(3,4-difluorophenyl)-cyclopropan-1-yl]-N-benzyl]amino}-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl}oxy)ethanol 
• 1383715-63-6 C₃₀H₃₄F₂N₆O₄S 
• 1383715-64-7 2-({(3aR,45,6R,6aS)-6-[7-{[[N-(1R,2S)-2-(3,4-difluorophenyl)-cyclopropan-1-yl]-N-tert-butoxycarbonyl]amino}-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl}oxy)-O-tertbutoxycarbonylethanol 
• 145783-15-9 4,6-dichloro-2-(propylsulfanyl)-5-pyrimidinamine 

Relevant articles and documents

Method for synthesizing 5-nitro-2-(propylthio) pyrimidine-4, 6-diol through continuous nitration

The invention discloses a method for synthesizing 5-nitro-2-(propyl thio) pyrimidine-4, 6-diol through continuous nitration. The synthesis method comprises the following steps: in a continuous flow reactor, taking nitrogen dioxide as a main nitrating agent, ozone as an auxiliary nitrating agent and 4, 6-dihydroxy-2-(propylthio) pyrimidine hydrochloride as a main raw material, carrying out nitration reaction to prepare the 5-nitro-2-(propylthio) pyrimidine-4, 6-diol compound. The method is extremely low in EHS risk, simple and convenient to operate, environment-friendly, high in production efficiency, high in yield, high in purity and suitable for industrial production.

Pyrimido triazole compound and medical application thereof (by machine translation)

The present invention relates to a compound of general (I) or a hydrate thereof or a pharmaceutically acceptable salt, thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the same or a pharmaceutically acceptable salt thereof, and use, of the compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament . The medicament is for anti-platelet aggregation and treatment of related diseases such as antithrombotic . (by machine translation)

Design, synthesis and in vitro biological evaluation of novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives containing a thiosemicarbazide moiety

A series of hybrid molecules containing [1,2,3]triazolo[4,5-d]pyrimidine and thiosemicarbazide moieties were designed, synthesized and evaluated for their antiproliferative activities against MGC-803, NCI-H1650 and PC-3 human cancer cells. Some of the synthesized compounds showed moderate to good activity against three selected cancer cell lines. Among these compounds, compound 29 displayed the most potent antiproliferative activity as well as good selectivity between cancer cells and normal cells. Further mechanism studies revealed that compound 29 could obviously inhibit the colony formation and migration of MGC-803 as well as induced apoptosis.

Preparation method for ticagrelor intermediate

The invention discloses a preparation method for a cagrelor intermediate. The preparation method comprises the following steps; step 1, reacting 2-nitro-1,3-malonic acid diester with sodium sulfocyanate and ammonium acetate in an aqueous solution of acetic acid so as to obtain a compound as shown in a formula II which is described in the specification; step 2, subjecting the compound as shown in the formula II to reflux in ethanol under the action of sodium alkoxide so as to obtain a compound as shown in a formula III which is described in the specification; step 3, subjecting the compound as shown in the formula III and 1-bromopropane to a contact reaction in 1,4-dioxane in the presence of alkali under the catalysis of zinc chloride; and step 4, subjecting a product of the step 3 and a chlorination reagent to a chlorination reaction in acetonitrile so as to obtain the ticagrelor intermediate 4,6-dichloro-5-nitro-2-(propylthio)pyridine. The preparation method provided by the invention has the advantages of few by-products, easy purification and high yield of the ticagrelor intermediate, usage of cheap and easily available raw materials and suitable for industrial production.

Pyrimidine and triazole containing LSD1 inhibitor and preparation method and application thereof

The invention belongs to the field of medicinal chemistry, and discloses a pyrimidine and triazole containing compound and a preparation method and application thereof in preparation of anti-cancer medicine with lysine specific demethylase 1 (LSD1) being a target. The general formula of the compound is shown in the drawing I. In-vitro LSD1 enzyme inhibition activity experiments prove that by inhibiting LSD1 activity, the compound has obvious inhibiting and killing effects on kinds of cancer cells and can be applied to preparation of the anti-cancer medicine as a further developed lead compound.

Pyrimidotriazole-containing LSD1 inhibitor, preparation method and application

Belonging to the field of pharmaceutical chemistry, the invention discloses a pyrimidotriazole compound, a preparation method and application of the compound with lysine specific demethylase 1 (LSD1) as the target in preparation of antitumor drugs. The general formula of the compound is shown as I in the specification. In vitro LSD1 enzyme inhibitory activity experiments prove that by inhibiting the activity of LSD1, the compound has obvious inhibition and killing effects on multiple tumor cells, can be applied as a lead compound for further development in preparation of antitumor drugs.

Inhibitor with pyrimido-triazole-tetrazole-thione LSD1 (lysine specific demethylase 1), preparation method of inhibitor and application

The invention belongs to the field of medicinal chemistry, and discloses a compound with pyrimido-triazole-tetrazole-thione structures, a preparation method of the compound and an application of the compound to preparation of anti-tumor medicines by taking lysine specific demethylase 1 (hereinafter referred to as LSD1) as a target. The general formula of the compound is as shown in the specification. In-vitro LSD1 inhibitory activity tests show that the compound has obvious inhibiting and killing functions on various tumor cells by inhibiting activity of the LSD1, can serve as a further developed lead and is applied to preparation of anti-tumor medicines.

Synthesis, Antiplatelet Aggregation Activity Evaluation and 3D-QSAR of a Series of Novel 6-Alkylamino(Alkoxyl)-2-Propylthio-8-Azapurine Nucleosides

A series of novel 6-alkylamino(alkoxyl)-2-propylthio-8-azapurine nucleosides were synthesized by an improved route, and the human antiplatelet aggregation activities of these new compounds were evaluated. A self-organizing molecular field analysis method was used to study the three-dimensional quantitative structure–activity relationship of these novel nucleosides. The results of the antiplatelet aggregation activity evaluation and analysis of the self-organizing molecular field analysis models through shape and electrostatic grids may provide a basis for the development of new and potent antiplatelet agents.

Design, synthesis and antiproliferative activity of thiazolo[5,4-d]pyrimidine derivatives through the atom replacement strategy

A series of thiazolo[5,4-d]pyrimidine derivatives were designed through the atom replacement strategy based on biologically validated scaffolds and then evaluated for their antiproliferative activities on cancer cell lines. The structure-activity relationship studies were conducted, leading to the identification of compound 22, which exhibited good antiproliferative activity against HGC-27 with an IC50 value of 1.22 μM and low toxicity against GES-1 cells. Mechanistic studies showed that compound 22 inhibited the colony formation and migration of HGC-27 as well as induced apoptosis. The western blot experiments proved that compound 22 up-regulated expression of Bax, down-regulated expression levels of Bcl-2 and cleaved caspased-3/9. These findings indicate that compound 22 may serve as a template for designing new agents for the treatment of human gastric cancers. The atom replacement strategy could be viable strategy for designing new anticancer drugs and may find its applications in drug design.

Design, synthesis, and biological evaluation of new thiazolo[5,4-: D] pyrimidine derivatives as potent antiproliferative agents

A series of thiazolo[5,4-d]pyrimidine derivatives were synthesized and evaluated for their antiproliferative activities against several human cancer cell lines. Structure-activity relationship studies were carried out, showing that most of the target compounds had good inhibition against the tested cell lines. Among them, compound 7i exhibited potent inhibition against human gastric cancer cells MGC-803 and HGC-27 with IC50 values of 4.64 and 5.07 μM, respectively and around 12-fold selectivity between MGC-803 and GES-1, indicating a relatively low toxicity to normal cells. The potency and low toxicity of compound 7i make the thiazolo[5,4-d]pyrimidine an attractive scaffold for designing new derivatives selectively targeting MGC-803 cells.